• Hematology
  • Ophthalmology
  • Neurology
  • Lysosomal Disorders
  • Oncology

Latest News

Athersys Modifies Endpoints in Multistem Trial for Ischemic Stroke
Athersys Modifies Endpoints in Multistem Trial for Ischemic Stroke

April 2nd 2023

The company also recently announced updates in the MATRICS-1 clinical trial for hemorrhagic trauma.

First Patient Dosed in Phase 1/1b Trial of PRGN-3007 CAR-T Cell Therapy in Solid Tumors, Hematologic Malignancies
First Patient Dosed in Phase 1/1b Trial of PRGN-3007 CAR-T Cell Therapy in Solid Tumors, Hematologic Malignancies

April 1st 2023

CGTLive’s Weekly Rewind – March 31, 2023
CGTLive’s Weekly Rewind – March 31, 2023

March 31st 2023

Caribou Biosciences Provides Updates on Allogeneic CAR-T Clinical Trials
Caribou Biosciences Provides Updates on Allogeneic CAR-T Clinical Trials

March 31st 2023

Matthew B. Harms, MD, on the Necessity of Tracking Gene Mutations in ALS
Matthew B. Harms, MD, on the Necessity of Tracking Gene Mutations in ALS

March 31st 2023

Video Interviews

Conference Coverage

View All
Matthew B. Harms, MD, on the Necessity of Tracking Gene Mutations in ALS
Matthew B. Harms, MD, on the Necessity of Tracking Gene Mutations in ALS

March 31st 2023

Rita Perlingeiro, PhD, on the Potential of iPS Cell-based Regenerative Medicine in Muscular Dystrophy
Rita Perlingeiro, PhD, on the Potential of iPS Cell-based Regenerative Medicine in Muscular Dystrophy

March 30th 2023

Matthew B. Harms, MD, on Gene Therapy’s Potential to Address Unmet Needs in ALS
Matthew B. Harms, MD, on Gene Therapy’s Potential to Address Unmet Needs in ALS

March 29th 2023

Rita Perlingeiro, PhD, on Using iPS Cells to Model Neuromuscular Disease
Rita Perlingeiro, PhD, on Using iPS Cells to Model Neuromuscular Disease

March 28th 2023

All News

© 2023 MJH Life Sciences

All rights reserved.